Business Context and Reporting Period
This Form 8-K Current Report was filed by AtriCure, Inc. on February 6, 2008. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board composition.
Material Changes
On February 6, 2008, the Board of Directors appointed Mark A. Collar as a director, effective immediately, to serve until the 2008 annual meeting of stockholders. This appointment introduces changes to the company's compensation obligations and equity structure.
Guidance, Outlook, and Management Commentary
The filing details the compensation package granted to Mr. Collar in connection with his appointment:
- Equity Grants: An initial option to purchase 50,000 shares of common stock, plus an option to purchase 10,000 shares at each annual meeting (provided he serves at least six months). Options are granted at fair market value with a ten-year term and vest one-fourth annually.
- Cash Compensation: An annual retainer of $20,000.
- Meeting Fees: $1,500 per in-person meeting and $500 per telephone meeting.
- Committee Fees: If serving on a committee as a non-chairperson, an additional $750 per in-person meeting and $350 per telephone meeting.
- Expenses: Reimbursement for all out-of-pocket expenses.
A press release announcing this appointment was issued on February 7, 2008.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 50,000 new option grants on potential dilution.
- Confirm the vesting schedule details for the initial grant versus subsequent annual grants.
- Review the company's total director compensation policy to ensure consistency with the terms granted to Mr. Collar.
- Check the date of the 2008 annual meeting of stockholders to determine the end of Mr. Collar's initial term.